APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Necrotizing Ulcerative Gingivitis (NUG)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Necrotizing Ulcerative Gingivitis (NUG) Market Outlook and Growth Opportunities 2026

Report ID 174016180430 December 2025192 pages

Choose your research edition.

Industry ResearchNecrotizing Ulcerative Gingivitis (NUG) Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Necrotizing Ulcerative Gingivitis (NUG) Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Necrotizing Ulcerative Gingivitis (NUG) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Necrotizing Ulcerative Gingivitis (NUG) Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Necrotizing Ulcerative Gingivitis (NUG) Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Necrotizing Ulcerative Gingivitis (NUG) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Necrotizing Ulcerative Gingivitis (NUG) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Necrotizing Ulcerative Gingivitis (NUG) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Necrotizing Ulcerative Gingivitis (NUG) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Necrotizing Ulcerative Gingivitis (NUG) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Necrotizing Ulcerative Gingivitis (NUG) market include Abbott Laboratories, Eli Lilly and Company, Hindustan Antibiotics, Otsuka Pharmaceutical, GlaxoSmithKline, Mylan, Merck, Novartis and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Necrotizing Ulcerative Gingivitis (NUG) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Necrotizing Ulcerative Gingivitis (NUG) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Necrotizing Ulcerative Gingivitis (NUG) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Necrotizing Ulcerative Gingivitis (NUG) market.

Necrotizing Ulcerative Gingivitis (NUG) Segment by Company

Abbott Laboratories

Eli Lilly and Company

Hindustan Antibiotics

Otsuka Pharmaceutical

GlaxoSmithKline

Mylan

Merck

Novartis

Sanofi

Teva Pharmaceutical

Necrotizing Ulcerative Gingivitis (NUG) Segment by Type

Medication

Surgery

Necrotizing Ulcerative Gingivitis (NUG) Segment by Application

Homecare

Pharmacies

Hospitals

Others

Necrotizing Ulcerative Gingivitis (NUG) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Necrotizing Ulcerative Gingivitis (NUG) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Necrotizing Ulcerative Gingivitis (NUG) key companies, revenue, market share, and recent developments.

3. To split the Necrotizing Ulcerative Gingivitis (NUG) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Necrotizing Ulcerative Gingivitis (NUG) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Necrotizing Ulcerative Gingivitis (NUG) significant trends, drivers, influence factors in global and regions.

6. To analyze Necrotizing Ulcerative Gingivitis (NUG) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Necrotizing Ulcerative Gingivitis (NUG) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Necrotizing Ulcerative Gingivitis (NUG) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Necrotizing Ulcerative Gingivitis (NUG).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Necrotizing Ulcerative Gingivitis (NUG) industry.

Chapter 3: Detailed analysis of Necrotizing Ulcerative Gingivitis (NUG) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Necrotizing Ulcerative Gingivitis (NUG) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Necrotizing Ulcerative Gingivitis (NUG) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Necrotizing Ulcerative Gingivitis (NUG) Industry Trends Table 2. Necrotizing Ulcerative Gingivitis (NUG) Industry Drivers Table 3. Necrotizing Ulcerative Gingivitis (NUG) Industry Opportunities and Challenges Table 4. Necrotizing Ulcerative Gingivitis (NUG) Industry Restraints Table 5. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Company (2021-2026) Table 7. Global Necrotizing Ulcerative Gingivitis (NUG) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Necrotizing Ulcerative Gingivitis (NUG) Key Company Manufacturing Base & Headquarters Table 9. Global Necrotizing Ulcerative Gingivitis (NUG) Company, Product Type & Application Table 10. Global Necrotizing Ulcerative Gingivitis (NUG) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Necrotizing Ulcerative Gingivitis (NUG) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Medication Table 15. Significant Companies of Surgery Table 16. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type (2021-2026) Table 20. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Homecare Table 22. Significant Companies of Pharmacies Table 23. Significant Companies of Hospitals Table 24. Significant Companies of Others Table 25. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application (2021-2026) Table 29. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application (2027-2032) Table 30. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Region (2021-2026) Table 33. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Region (2027-2032) Table 35. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value Market Share by Country (2021-2026) Table 38. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value Market Share by Country (2027-2032) Table 40. Abbott Laboratories Company Information Table 41. Abbott Laboratories Business Overview Table 42. Abbott Laboratories Necrotizing Ulcerative Gingivitis (NUG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Abbott Laboratories Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 44. Abbott Laboratories Recent Development Table 45. Eli Lilly and Company Company Information Table 46. Eli Lilly and Company Business Overview Table 47. Eli Lilly and Company Necrotizing Ulcerative Gingivitis (NUG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Eli Lilly and Company Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 49. Eli Lilly and Company Recent Development Table 50. Hindustan Antibiotics Company Information Table 51. Hindustan Antibiotics Business Overview Table 52. Hindustan Antibiotics Necrotizing Ulcerative Gingivitis (NUG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Hindustan Antibiotics Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 54. Hindustan Antibiotics Recent Development Table 55. Otsuka Pharmaceutical Company Information Table 56. Otsuka Pharmaceutical Business Overview Table 57. Otsuka Pharmaceutical Necrotizing Ulcerative Gingivitis (NUG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Otsuka Pharmaceutical Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 59. Otsuka Pharmaceutical Recent Development Table 60. GlaxoSmithKline Company Information Table 61. GlaxoSmithKline Business Overview Table 62. GlaxoSmithKline Necrotizing Ulcerative Gingivitis (NUG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. GlaxoSmithKline Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 64. GlaxoSmithKline Recent Development Table 65. Mylan Company Information Table 66. Mylan Business Overview Table 67. Mylan Necrotizing Ulcerative Gingivitis (NUG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Mylan Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 69. Mylan Recent Development Table 70. Merck Company Information Table 71. Merck Business Overview Table 72. Merck Necrotizing Ulcerative Gingivitis (NUG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Merck Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 74. Merck Recent Development Table 75. Novartis Company Information Table 76. Novartis Business Overview Table 77. Novartis Necrotizing Ulcerative Gingivitis (NUG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Novartis Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 79. Novartis Recent Development Table 80. Sanofi Company Information Table 81. Sanofi Business Overview Table 82. Sanofi Necrotizing Ulcerative Gingivitis (NUG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Sanofi Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 84. Sanofi Recent Development Table 85. Teva Pharmaceutical Company Information Table 86. Teva Pharmaceutical Business Overview Table 87. Teva Pharmaceutical Necrotizing Ulcerative Gingivitis (NUG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Teva Pharmaceutical Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 89. Teva Pharmaceutical Recent Development Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. Necrotizing Ulcerative Gingivitis (NUG) Product Image Figure 2. Global Necrotizing Ulcerative Gingivitis (NUG) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Necrotizing Ulcerative Gingivitis (NUG) Market Size (2021-2032) & (US$ Million) Figure 4. Global Necrotizing Ulcerative Gingivitis (NUG) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Medication Image Figure 8. Surgery Image Figure 9. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type (2021-2032) Figure 12. Homecare Image Figure 13. Pharmacies Image Figure 14. Hospitals Image Figure 15. Others Image Figure 16. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application (2021-2032) Figure 19. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Necrotizing Ulcerative Gingivitis (NUG) Sales Value (2021-2032) & (US$ Million) Figure 22. North America Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Necrotizing Ulcerative Gingivitis (NUG) Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Necrotizing Ulcerative Gingivitis (NUG) Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Necrotizing Ulcerative Gingivitis (NUG) Sales Value (2021-2032) & (US$ Million) Figure 28. South America Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Necrotizing Ulcerative Gingivitis (NUG) Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Medication
  • Surgery
Applications
  • Homecare
  • Pharmacies
  • Hospitals
  • Others
Companies covered
  • Abbott Laboratories
  • Eli Lilly and Company
  • Hindustan Antibiotics
  • Otsuka Pharmaceutical
  • GlaxoSmithKline
  • Mylan
  • Merck
  • Novartis
  • Sanofi
  • Teva Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Necrotizing Ulcerative Gingivitis (NUG) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Necrotizing Ulcerative Gingivitis (NUG) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Necrotizing Ulcerative Gingivitis (NUG) Market Dynamics
  1. 2.1 Necrotizing Ulcerative Gingivitis (NUG) Industry Trends
  2. 2.2 Necrotizing Ulcerative Gingivitis (NUG) Industry Drivers
  3. 2.3 Necrotizing Ulcerative Gingivitis (NUG) Industry Opportunities and Challenges
  4. 2.4 Necrotizing Ulcerative Gingivitis (NUG) Industry Restraints
3 Necrotizing Ulcerative Gingivitis (NUG) Market by Company
  1. 3.1 Global Necrotizing Ulcerative Gingivitis (NUG) Company Revenue Ranking in 2025
  2. 3.2 Global Necrotizing Ulcerative Gingivitis (NUG) Revenue by Company (2021-2026)
  3. 3.3 Global Necrotizing Ulcerative Gingivitis (NUG) Company Ranking (2024-2026)
  4. 3.4 Global Necrotizing Ulcerative Gingivitis (NUG) Company Manufacturing Base and Headquarters
  5. 3.5 Global Necrotizing Ulcerative Gingivitis (NUG) Company Product Type and Application
  6. 3.6 Global Necrotizing Ulcerative Gingivitis (NUG) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Necrotizing Ulcerative Gingivitis (NUG) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Necrotizing Ulcerative Gingivitis (NUG) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Necrotizing Ulcerative Gingivitis (NUG) Market by Type
  1. 4.1 Necrotizing Ulcerative Gingivitis (NUG) Type Introduction
  2. 4.1.1 Medication
  3. 4.1.2 Surgery
  4. 4.2 Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Type
  5. 4.2.1 Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Type (2021-2032)
  7. 4.2.3 Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type (2021-2032)
5 Necrotizing Ulcerative Gingivitis (NUG) Market by Application
  1. 5.1 Necrotizing Ulcerative Gingivitis (NUG) Application Introduction
  2. 5.1.1 Homecare
  3. 5.1.2 Pharmacies
  4. 5.1.3 Hospitals
  5. 5.1.4 Others
  6. 5.2 Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Application
  7. 5.2.1 Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Application (2021-2032)
  9. 5.2.3 Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application (2021-2032)
6 Necrotizing Ulcerative Gingivitis (NUG) Regional Value Analysis
  1. 6.1 Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Necrotizing Ulcerative Gingivitis (NUG) Sales Value (2021-2032)
  7. 6.3.2 North America Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Necrotizing Ulcerative Gingivitis (NUG) Sales Value (2021-2032)
  10. 6.4.2 Europe Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Necrotizing Ulcerative Gingivitis (NUG) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Necrotizing Ulcerative Gingivitis (NUG) Sales Value (2021-2032)
  16. 6.6.2 South America Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Necrotizing Ulcerative Gingivitis (NUG) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Country, 2025 VS 2032
7 Necrotizing Ulcerative Gingivitis (NUG) Country-level Value Analysis
  1. 7.1 Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Necrotizing Ulcerative Gingivitis (NUG) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Necrotizing Ulcerative Gingivitis (NUG) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Necrotizing Ulcerative Gingivitis (NUG) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott Laboratories
  2. 8.1.1 Abbott Laboratories Company Information
  3. 8.1.2 Abbott Laboratories Business Overview
  4. 8.1.3 Abbott Laboratories Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Laboratories Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  6. 8.1.5 Abbott Laboratories Recent Developments
  7. 8.2 Eli Lilly and Company
  8. 8.2.1 Eli Lilly and Company Company Information
  9. 8.2.2 Eli Lilly and Company Business Overview
  10. 8.2.3 Eli Lilly and Company Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly and Company Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  12. 8.2.5 Eli Lilly and Company Recent Developments
  13. 8.3 Hindustan Antibiotics
  14. 8.3.1 Hindustan Antibiotics Company Information
  15. 8.3.2 Hindustan Antibiotics Business Overview
  16. 8.3.3 Hindustan Antibiotics Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Hindustan Antibiotics Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  18. 8.3.5 Hindustan Antibiotics Recent Developments
  19. 8.4 Otsuka Pharmaceutical
  20. 8.4.1 Otsuka Pharmaceutical Company Information
  21. 8.4.2 Otsuka Pharmaceutical Business Overview
  22. 8.4.3 Otsuka Pharmaceutical Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Otsuka Pharmaceutical Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  24. 8.4.5 Otsuka Pharmaceutical Recent Developments
  25. 8.5 GlaxoSmithKline
  26. 8.5.1 GlaxoSmithKline Company Information
  27. 8.5.2 GlaxoSmithKline Business Overview
  28. 8.5.3 GlaxoSmithKline Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  30. 8.5.5 GlaxoSmithKline Recent Developments
  31. 8.6 Mylan
  32. 8.6.1 Mylan Company Information
  33. 8.6.2 Mylan Business Overview
  34. 8.6.3 Mylan Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Mylan Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  36. 8.6.5 Mylan Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Novartis
  44. 8.8.1 Novartis Company Information
  45. 8.8.2 Novartis Business Overview
  46. 8.8.3 Novartis Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novartis Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  48. 8.8.5 Novartis Recent Developments
  49. 8.9 Sanofi
  50. 8.9.1 Sanofi Company Information
  51. 8.9.2 Sanofi Business Overview
  52. 8.9.3 Sanofi Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sanofi Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  54. 8.9.5 Sanofi Recent Developments
  55. 8.10 Teva Pharmaceutical
  56. 8.10.1 Teva Pharmaceutical Company Information
  57. 8.10.2 Teva Pharmaceutical Business Overview
  58. 8.10.3 Teva Pharmaceutical Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Teva Pharmaceutical Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  60. 8.10.5 Teva Pharmaceutical Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst